WX-554

DB21749InvestigationalSmall molecule

WX-554 is under investigation in clinical trial NCT01581060 (Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours).

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Dual specificity mitogen-activated protein kinase kinase 2
Curator reviewed
Formula / weight: C₁₈H₁₆FIN₄OS · 482.32 g/mol (avg)
Code names: WX-554

Resolves to

Compound

UNII36TRH66AA6CAS945529-91-9

Structure

InChIKeyDJIBEZXMCYNIQJ-UHFFFAOYSA-NSMILESNCC1CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)SC2=NC=CC=C12

Targets

Q02750MAP2K1P36507MAP2K2

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with WX-554, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account